Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma
- PMID: 20002769
- DOI: 10.1111/j.1365-2559.2009.03449.x
Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma
Abstract
Aims: The variation in cytoplasmic staining and growth pattern makes differential diagnosis of chromophobe renal cell carcinoma (RCC), especially from renal oncocytomas (RO), uncertain. The aim was to find an immunohistochemical marker to improve the diagnosis of chromophobe RCC.
Methods and results: The expression profile of renal cell tumours was established using the Affymetrix HG U133 Plus 2.0 microarray. After performing hierarchical clustering we selected the best 50 genes and analysed 24 of them by reverse transcriptase-polymerase chain reaction. TMC5, RBM35, SPINK7, CD82/KAI1 and GLIS3 were expressed specifically in chromophobe RCCs. Immunohistochemical studies confirmed the specificity of CD82/KAI1. Analysis of tissue microarrays containing all major types of renal neoplasm revealed immunopositivity for CD82/KAI1 in 78% (69/88) of chromophobe RCCs but in only 3% (6/220) of conventional or clear cell RCCs. All 90 ROs and 171 papillary RCCs were immunonegative for CD82/KAI1. To confirm the specificity of antibody by immunoblotting, we transfected HEK293 cells with an expression vector containing the full-length CD82/KAI1.
Conclusions: CD82/KAI1 is an excellent marker for distinguishing chromophobe RCCs from other types of renal cell tumours, especially from ROs with overlapping phenotype.
Similar articles
-
Expression of vitamin D3 receptor in kidney tumors.Hum Pathol. 2006 Oct;37(10):1268-78. doi: 10.1016/j.humpath.2006.04.029. Epub 2006 Jul 27. Hum Pathol. 2006. PMID: 16949927
-
S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma.Histopathology. 2007 Apr;50(5):642-7. doi: 10.1111/j.1365-2559.2007.02655.x. Histopathology. 2007. PMID: 17394501
-
Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.J Urol. 2009 May;181(5):2305-11. doi: 10.1016/j.juro.2009.01.003. Epub 2009 Mar 19. J Urol. 2009. PMID: 19303095
-
Molecular pathology of chromophobe renal cell carcinoma: a review.Int J Urol. 2010 Jul;17(7):592-600. doi: 10.1111/j.1442-2042.2010.02558.x. Int J Urol. 2010. PMID: 20590942 Review.
-
Recent advances of immunohistochemistry for diagnosis of renal tumors.Pathol Int. 2013 Aug;63(8):381-90. doi: 10.1111/pin.12080. Pathol Int. 2013. PMID: 23957913 Review.
Cited by
-
Sciellin is a marker for papillary renal cell tumours.Virchows Arch. 2015;467:695-700. doi: 10.1007/s00428-015-1856-y. Epub 2015 Oct 16. Virchows Arch. 2015. PMID: 26475151
-
Utility of immunohistochemical analysis of KAI1, epithelial-specific antigen, and epithelial-related antigen for distinction of chromophobe renal cell carcinoma, an eosinophilic variant from renal oncocytoma.Med Mol Morphol. 2012 Jun;45(2):98-104. doi: 10.1007/s00795-011-0546-3. Epub 2012 Jun 21. Med Mol Morphol. 2012. PMID: 22718295
-
Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours.Int J Biol Sci. 2009 Jul 29;5(6):517-27. doi: 10.7150/ijbs.5.517. Int J Biol Sci. 2009. PMID: 19680475 Free PMC article.
-
Transmembrane channel-like 5 drives hepatocellular carcinoma progression by regulating epithelial-mesenchymal transition.World J Clin Oncol. 2025 Mar 24;16(3):94091. doi: 10.5306/wjco.v16.i3.94091. World J Clin Oncol. 2025. PMID: 40130046 Free PMC article.
-
TRANSCRIPTION FACTOR GLI-SIMILAR 3 (GLIS3): IMPLICATIONS FOR THE DEVELOPMENT OF CONGENITAL HYPOTHYROIDISM.J Endocrinol Diabetes Obes. 2014 Apr;2(2):1024. J Endocrinol Diabetes Obes. 2014. PMID: 25133201 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials